title: Tazarotene plus UVB phototherapy in the treatment of psoriasis.
abstract: BACKGROUND
  The addition of oral retinoids to phototherapy may accelerate and enhance antipsoriatic efficacy, but can result in systemic adverse events and additional laboratory monitoring costs.
  
  
  OBJECTIVE
  Our purpose was to determine whether the topical addition of tazarotene to UVB phototherapy improves efficacy without problems related to photosensitivity.
  
  
  METHODS
  Bilateral target plaques were randomized to receive two of the following, one on each plaque once daily for 14 days: tazarotene 0.1% gel, vehicle gel, or no treatment. Thereafter, the same treatments were continued 3 times per week, plus UVB phototherapy 3 times per week, for an additional 67 days.
  
  
  RESULTS
  Tazarotene plus UVB phototherapy achieved faster and significantly greater reductions in plaque elevation and scaling throughout treatment and achieved at least 50% improvement from the pretreatment baseline with a significantly lower median cumulative UVB exposure than vehicle gel plus UVB light or UVB phototherapy alone. No case of unusual photosensitivity was noted in the tazarotene plus UVB treatment group.
  
  
  CONCLUSIONS
  The addition of tazarotene to UVB phototherapy improves and accelerates efficacy and maintains acceptable safety and tolerability.
authors.affiliation: Psoriasis Treatment Center, University of California San Francisco, 94118, USA.
authors.forename: J Y
authors.initials: JY
authors.lastname: Koo
authors.forename: N J
authors.initials: NJ
authors.lastname: Lowe
authors.forename: D A
authors.initials: DA
authors.lastname: Lew-Kaya
authors.forename: A I
authors.initials: AI
authors.lastname: Vasilopoulos
authors.forename: J C
authors.initials: JC
authors.lastname: Lue
authors.forename: J
authors.initials: J
authors.lastname: Sefton
authors.forename: J R
authors.initials: JR
authors.lastname: Gibson
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D011565:Psoriasis / Q000628:therapy*; D016896:Treatment Outcome; D014467:Ultraviolet Therapy; D012176:Retinoids
chemical_list: D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids